Li et al. (2020) proposed that upregulated writers (DNMT1, DNMT3A, and DNMT3B) facilitated hypermethylation and downregulation of BAD and INPPL1 in colitis-associated cancer. Xu et al. (2019) recommended TET2 (eraser) activity as a biomarker to predict the efficacy of anti-PD-1/PD-L1 treatment and patient response and the stimulation of TET2 activity as adjunct immunotherapy for CC. The MBD2 (reader) antigen only reacted with the serum of CC patients but not with the serum of normal blood donors (Martin et al., 2008). The gene discussed is TET2; the disease is cancer.